381 related articles for article (PubMed ID: 33590260)
1. Efficacy of one-day versus multiple-day dexamethasone for chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based chemotherapy: a propensity score-matched analysis.
Hayashi T; Shimokawa M; Mizuki F; Matsuo K; Kawada K; Nakano T; Egawa T
Support Care Cancer; 2021 Sep; 29(9):5029-5035. PubMed ID: 33590260
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Palonosetron, 1-Day Dexamethasone, and Aprepitant in Patients Undergoing Carboplatin-Based Chemotherapy.
Hayashi T; Shimokawa M; Matsuo K; Uchiyama M; Kawada K; Nakano T; Egawa T
Oncology; 2023; 101(9):584-590. PubMed ID: 37276851
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis.
Hayashi T; Shimokawa M; Matsuo K; Iihara H; Kawada K; Nakano T; Egawa T
BMC Cancer; 2021 Jan; 21(1):74. PubMed ID: 33451299
[TBL] [Abstract][Full Text] [Related]
4. 5HT
Hayashi T; Shimokawa M; Matsuo K; Nishimura J; Iihara H; Nakano T; Egawa T
Cancer Sci; 2021 Feb; 112(2):744-750. PubMed ID: 33274555
[TBL] [Abstract][Full Text] [Related]
5. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M
Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012
[TBL] [Abstract][Full Text] [Related]
7. Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial.
van der Vorst MJDL; Toffoli EC; Beusink M; van Linde ME; van Voorthuizen T; Brouwer S; van Zweeden AA; Vrijaldenhoven S; Berends JC; Berkhof J; Verheul HMW
Oncologist; 2021 Jan; 26(1):e173-e181. PubMed ID: 32735029
[TBL] [Abstract][Full Text] [Related]
8. Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients.
Iihara H; Shimokawa M; Abe M; Hayasaki Y; Fujita Y; Nagasawa Y; Sakurai M; Matsuoka R; Suzuki A; Morishige K
BMJ Open; 2019 Jan; 9(1):e024357. PubMed ID: 30782732
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Single-dose First-generation 5-HT
Kaito D; Iihara H; Funaguchi N; Endo J; Ito F; Yanase K; Toyoshi S; Sasaki Y; Hirose C; Arai N; Kitahora M; Ohno Y; Itoh Y; Minatoguchi S
Anticancer Res; 2017 Apr; 37(4):1965-1970. PubMed ID: 28373467
[TBL] [Abstract][Full Text] [Related]
10. Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin.
Furukawa N; Kanayama S; Tanase Y; Ito F
Support Care Cancer; 2015 Nov; 23(11):3317-22. PubMed ID: 25947257
[TBL] [Abstract][Full Text] [Related]
11. Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis.
Yamamoto S; Iihara H; Uozumi R; Kawazoe H; Tanaka K; Fujita Y; Abe M; Imai H; Karayama M; Hayasaki Y; Hirose C; Suda T; Nakamura K; Suzuki A; Ohno Y; Morishige KI; Inui N
BMC Cancer; 2022 Mar; 22(1):310. PubMed ID: 35321690
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study.
Ito F; Furukawa N
Support Care Cancer; 2017 Jun; 25(6):1941-1945. PubMed ID: 28160077
[TBL] [Abstract][Full Text] [Related]
13. One-Day Versus Three-Day Dexamethasone with NK1RA for Patients Receiving Carboplatin and Moderate Emetogenic Chemotherapy: A Network Meta-analysis.
Watanabe D; Iihara H; Fujii H; Makiyama A; Nishida S; Suzuki A
Oncologist; 2022 Jun; 27(6):e524-e532. PubMed ID: 35427418
[TBL] [Abstract][Full Text] [Related]
14. A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan.
Iihara H; Shimokawa M; Hayashi T; Kawazoe H; Saeki T; Aiba K; Tamura K
Oncologist; 2020 Feb; 25(2):e373-e380. PubMed ID: 32043774
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
A Mahrous M; A El-Azab G; A Tawfik H
Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131).
Nishio S; Aihara S; Shimokawa M; Fujishita A; Taniguchi S; Hachisuga T; Yanazume S; Kobayashi H; Murakami F; Numa F; Kotera K; Okura N; Toki N; Yokoyama M; Ushijima K
J Gynecol Oncol; 2018 Sep; 29(5):e77. PubMed ID: 30022637
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Antiemetic Effect of Aprepitant/granisetron and Palonosetron Combined with Dexamethasone in Gynecological Cancer Patients Treated with Paclitaxel and Carboplatin Combination Regimen.
Obayashi K; Nagamine A; Yashima H; Ohshima S; Uchiyama C; Takahashi E; Takahashi Y; Araki T; Yamamoto K
Pharmazie; 2022 May; 77(5):157-161. PubMed ID: 35655378
[TBL] [Abstract][Full Text] [Related]
18. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following paclitaxel and carboplatin in patients with gynecologic cancers: A randomized, multicenter, phase-II trial.
Matsuura M; Satohisa S; Teramoto M; Tanaka R; Iwasaki M; Nishikawa A; Mizunuma M; Tanaka S; Hayakawa O; Saito T
J Obstet Gynaecol Res; 2015 Oct; 41(10):1607-13. PubMed ID: 26199182
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
Kusagaya H; Inui N; Karayama M; Fujisawa T; Enomoto N; Kuroishi S; Nakamura Y; Matsuda H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Yamada T; Shirai T; Hayakawa H; Suda T
Lung Cancer; 2015 Dec; 90(3):410-6. PubMed ID: 26791800
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the dexamethasone-sparing triplet regimen for preventing cisplatin-induced emesis: a combined analysis.
Celio L; Bonizzoni E; Montani E; Aapro M
Future Oncol; 2022 Sep; 18(30):3389-3397. PubMed ID: 36017782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]